Back

Comprehensive molecular characterization of cutaneous squamous cell carcinoma reveals determinants of metastatic progression

Rentroia-Pacheco, B.; Sharma, H.; Pozza, L.; Traets, J. J. H.; Tandukar, B.; Steijlen, O. F. M.; Ruiter, R.; Cruz-Pacheco, N.; Huigh, D.; Van Hoeck, A.; Chen, Y.-T.; Infante, B.; Baskurt, D.; Arunachalam, V.; Eggermont, C. J.; Bas-Cristobal Menendez, A.; Nijsten, T.; van de Werken, H. J. G.; Mooyaart, A. L.; Bellomo, D.; Wakkee, M.; Shain, A. H.; Hollestein, L. M.

2026-07-20 oncology
10.64898/2026.07.17.26358051 medRxiv
Show abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of cancer worldwide. While most cSCCs are not life-threatening, 2-5% of patients develop metastases. To better understand what causes some cSCCs to progress to metastatic disease, we assembled a nationwide cohort of 19,120 patients with clinico-pathologically annotated tumors linked to metastatic outcome. RNA-sequencing was performed on 378 tumors, and whole-exome sequencing on 147, with balanced numbers of tumors that progressed to metastatic disease (cases) and did not (controls). UV radiation was the dominant mutational signature with additional contributions from aging, APOBEC activity, and, in immunosuppressed patients, azathioprine exposure. We identified 38 genes under selection across a core set of signaling pathways. Gene expression clusters were primarily associated with the differentiation state of tumor cells and secondarily with the composition of the tumor microenvironment. Several mutational and transcriptional programs were associated with metastasis, including a dedifferentiated gene expression signature, activating mutations in the RAS signaling pathway, loss-of-function alterations in the SWI/SNF chromatin remodeling complex, and specific arm-level copy number alterations. A 23-gene expression signature was built to predict metastasis from primary cSCC tissue. The signature was validated in two independent cohorts (N=102 and 52), where it predicted metastasis independently of staging systems. Together, these findings provide the most detailed molecular portrait of cSCC to date and establish an assay for risk stratification suitable for clinical implementation.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 9%
18.3%
2
Cancers
213 papers in training set
Top 0.2%
12.8%
3
British Journal of Dermatology
11 papers in training set
Top 0.1%
11.8%
4
eLife
5828 papers in training set
Top 25%
4.8%
5
JNCI: Journal of the National Cancer Institute
19 papers in training set
Top 0.1%
4.3%
50% of probability mass above
6
Cancer Research
130 papers in training set
Top 0.9%
4.0%
7
Journal of Clinical Investigation
179 papers in training set
Top 2%
3.2%
8
European Journal of Cancer
11 papers in training set
Top 0.1%
2.6%
9
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 24%
2.1%
10
Scientific Reports
3612 papers in training set
Top 51%
1.9%
11
Cell Reports
1498 papers in training set
Top 19%
1.7%
12
Cancer Cell
42 papers in training set
Top 0.8%
1.7%
13
Frontiers in Oncology
103 papers in training set
Top 2%
1.5%
14
Cell Reports Medicine
153 papers in training set
Top 3%
1.5%
15
The American Journal of Human Genetics
234 papers in training set
Top 2%
1.3%
16
Annals of Oncology
14 papers in training set
Top 0.2%
1.1%
17
Nature Cancer
39 papers in training set
Top 1%
1.1%
18
Molecular Therapy
81 papers in training set
Top 1%
1.1%
19
International Journal of Cancer
49 papers in training set
Top 1.0%
1.1%
20
npj Breast Cancer
23 papers in training set
Top 0.4%
1.0%
21
Clinical Cancer Research
64 papers in training set
Top 2%
0.9%
22
British Journal of Cancer
49 papers in training set
Top 1%
0.9%
23
Journal of Translational Medicine
57 papers in training set
Top 2%
0.8%
24
Communications Biology
993 papers in training set
Top 31%
0.8%
25
Cancer Epidemiology, Biomarkers & Prevention
20 papers in training set
Top 0.4%
0.8%
26
npj Precision Oncology
53 papers in training set
Top 2%
0.8%
27
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 2%
0.8%